European Wellness Biomedical Group and AK International to Bring Biological Regenerative Medicine Solutions to Pakistan and UAE
PR94971
DUBAI, United Arab Emirates, March 15, 2022 /PRNewswire=KYODO JBN/ --
European Wellness Biomedical Group (EWBG) has signed a Memorandum of Agreement
(MOA) with Dubai-based AK International LLC (AKI), partnering together to
undertake a number of joint venture businesses in Pakistan and the MENA region
that focus on providing biological regenerative medicine services and solutions
to the community.
In the signing session held on 1st March 2022, the two parties agreed to pool
their respective resources and expertise on a three-phase joint venture plan.
Phase 1 involves the registration, importing, distribution and commercializing
of EWBG award-winning Swiss, German and European biotech products and
biological APIs. AKI will be contributing their extensive distribution network
in the region and expertise in the aesthetics market, including wide-reaching
internationally accredited educational programs by European Wellness Academy
and conducted AKI's academic entity, Aesthetic Knowledge Institute.
Phase 2 will see the development of exclusive EWBG branded wellness centers for
age reversal, longevity, and disease prevention in these territories. These
wellness centers will be offering biological regenerative solutions including a
biological laboratory with cleanrooms for the development of autologous or
allogenic stem cells and EWBG's expertise in proprietary cell therapy,
including but not limited to their patented precursor stem cell technology,
biotherapeutics comprising stem cells and cell-based products, biomolecular
peptides and botanicals, compounded therapeutics and parenteral nutrition,
cosmeceuticals, food supplements, natural health products, and skincare and
cosmetics.
Finally, phase 3 of the joint-venture will foray into the digital health
ecosystem. This entails a synergistic integration of AKI's innovative mobile
app 'Health Interface' (HI), developed by Artelir Inc., with EWBG's global
network of 26 medical wellness hospitals and youth restorative anti-aging
centers, biological health solutions and services.
AKI and EWBG, through its Swiss and German entities namely Nexgen Biopharma Ltd
and Stellar Biomolecular Innovations Inc., have previously entered into two
separate joint venture agreements for the distribution of MF3 and MF PLUS brand
and products on 29th March 2021.
The two parties were represented by EWBG Co-Founder and Chairman, Prof. Dr.
Mike Chan and AKI Director Dr. Aasif Ali Siddiqui respectively.
About European Wellness Biomedical Group
Founded in 1991, EWBG is an award-winning European group most renowned for its
pioneering developments in precursor stem cell therapeutics, immunomodulation,
biological peptides, and biological regenerative medicine. The Group's
portfolio comprises multinational business divisions that operate in the
emerging fields of biological regenerative medicine; and product distribution
across 80 countries. The Group also owns a growing network of 26
internationally-accredited Wellness Centers globally. Today, the Group is
headquartered in Germany and Kota Kinabalu, Malaysia (Asia Pacific) and its own
manufacturing facilities in Germany, Switzerland, United States, United Kingdom
and the European Union.
Source: European Wellness Biomedical Group
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=417055
Caption: In the MoA signing, the two parties were represented by EWBG Co-Founder and
Chairman Prof. Dr. Mike Chan and AKI Director Dr. Aasif Ali Siddiqui
respectively.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。